INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings

INDAPTUS THERAPEUTICS ($INDP) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.38 per share, beating estimates of -$0.45 by $0.07. The company also reported revenue of $0, equaling estimates of $0 by $0.

You can see Quiver Quantitative's $INDP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

INDAPTUS THERAPEUTICS Hedge Fund Activity

We have seen 7 institutional investors add shares of INDAPTUS THERAPEUTICS stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• SUSQUEHANNA INTERNATIONAL GROUP, LLP added 17,829 shares (+inf%) to their portfolio in Q4 2024, for an estimated $15,013
• TWO SIGMA SECURITIES, LLC added 16,620 shares (+inf%) to their portfolio in Q4 2024, for an estimated $13,995
• CITADEL ADVISORS LLC removed 15,390 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $12,959
• GEODE CAPITAL MANAGEMENT, LLC added 8,989 shares (+12.3%) to their portfolio in Q4 2024, for an estimated $7,569
• UBS GROUP AG added 2,001 shares (+383.3%) to their portfolio in Q4 2024, for an estimated $1,685
• TOWER RESEARCH CAPITAL LLC (TRC) removed 1,299 shares (-27.0%) from their portfolio in Q4 2024, for an estimated $1,093
• RENAISSANCE TECHNOLOGIES LLC added 600 shares (+2.2%) to their portfolio in Q4 2024, for an estimated $505

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.